PLEASANTON, Calif., Sept. 13 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today award of a two year, $1 million Phase I SBIR grant from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The grant in collaboration with Dr. Catharine Bosio at Colorado State University (CSU) involves the development of prophylactic and therapeutic approach for the treatment of Francisella tularensis (Tularemia), a category A Biodefense priority pathogen. Juvaris' novel and potent immunostimulant technology will be tested by Dr. Bosio in rodent models using the highly virulent F. tularensis Schu4 bacterial strain. The feasibility of the novel approach is supported by preclinical data generated by Juvaris and Dr. Bosio demonstrating significant protection in a rodent Tularemia infection model.
